High Court Asked To Weigh Inequitable Conduct Ruling

Law360, New York (January 29, 2009, 12:00 AM EST) -- Subsidiaries of Sanofi-Aventis have asked the U.S. Supreme Court to weigh in on a decision that upheld a lower court’s finding that Aventis’ patents for its anti-clotting drug Lovenox were invalid due to inequitable conduct.

Aventis Pharma SA and Aventis Pharmaceuticals Inc. filed a petition for a writ of certiorari with the Supreme Court on Jan. 23 that seeks to reverse the U.S. Court of Appeals for the Federal Circuit’s 2-1 opinion that affirmed a district court’s ruling in favor of generics makers Amphastar Pharmaceuticals Inc....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.